Interestingly, in 2007, Conrad et al. submitted a patent on LAMTOR3 (Mp1) as a diagnostic and therapeutic target for breast cancer treatment and prevention (United States patent Application No. US 2007/0172843 A1; International publication nr. Here, LAMTOR3 is linked to breast cancer.